Coupling to Gq Signaling Is Required for Cardioprotection by an Alpha-1A-Adrenergic Receptor Agonist.
Adrenergic alpha-1 Receptor Agonists
/ pharmacology
Amino Acid Substitution
Animals
Cardiotonic Agents
/ pharmacology
Cells, Cultured
GTP-Binding Protein alpha Subunits, Gq-G11
/ metabolism
Imidazoles
/ pharmacology
Male
Mice
Mice, Inbred C57BL
Mitogen-Activated Protein Kinase 1
/ metabolism
Mitogen-Activated Protein Kinase 3
/ metabolism
Myocardial Contraction
Myocytes, Cardiac
/ drug effects
Phosphoinositide Phospholipase C
/ metabolism
Protein Domains
Receptors, Adrenergic, alpha-1
/ chemistry
Signal Transduction
Tetrahydronaphthalenes
/ pharmacology
Erk1 and Erk2 pathway
Gtp-binding protein alpha subunit, Gq
cardiac myocytes
cytoprotection
heart failure, systolic
receptors, adrenergic, alpha1A
Journal
Circulation research
ISSN: 1524-4571
Titre abrégé: Circ Res
Pays: United States
ID NLM: 0047103
Informations de publication
Date de publication:
13 09 2019
13 09 2019
Historique:
pubmed:
21
8
2019
medline:
7
7
2020
entrez:
21
8
2019
Statut:
ppublish
Résumé
Gq signaling in cardiac myocytes is classically considered toxic. Targeting Gq directly to test this is problematic, because cardiac myocytes have many Gq-coupled receptors. Test whether Gq coupling is required for the cardioprotective effects of an alpha-1A-AR (adrenergic receptor) agonist. In recombinant cells, a mouse alpha-1A-AR with a 6-residue substitution in the third intracellular loop does not couple to Gq signaling. Here we studied a knockin mouse with this alpha-1A-AR mutation. Heart alpha-1A receptor levels and antagonist affinity in the knockin were identical to wild-type. In wild-type cardiac myocytes, the selective alpha-1A agonist A61603-stimulated phosphoinositide-phospholipase C and myocyte contraction. In myocytes with the alpha-1A knockin, both A61603 effects were absent, indicating that Gq coupling was absent. Surprisingly, A61603 activation of cardioprotective ERK (extracellular signal-regulated kinase) was markedly impaired in the KI mutant myocytes, and A61603 did not protect mutant myocytes from doxorubicin toxicity in vitro. Similarly, mice with the α1A KI mutation had increased mortality after transverse aortic constriction, and A61603 did not rescue cardiac function in mice with the Gq coupling-defective alpha-1A receptor. Gq coupling is required for cardioprotection by an alpha-1A-AR agonist. Gq signaling can be adaptive.
Identifiants
pubmed: 31426700
doi: 10.1161/CIRCRESAHA.118.314416
pmc: PMC6742539
mid: NIHMS1537739
doi:
Substances chimiques
A 61603
0
Adrenergic alpha-1 Receptor Agonists
0
Cardiotonic Agents
0
Imidazoles
0
Receptors, Adrenergic, alpha-1
0
Tetrahydronaphthalenes
0
Mitogen-Activated Protein Kinase 1
EC 2.7.11.24
Mitogen-Activated Protein Kinase 3
EC 2.7.11.24
Phosphoinositide Phospholipase C
EC 3.1.4.11
GTP-Binding Protein alpha Subunits, Gq-G11
EC 3.6.5.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
699-706Subventions
Organisme : BLRD VA
ID : I01 BX000740
Pays : United States
Organisme : BLRD VA
ID : I01 BX004314
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL031113
Pays : United States
Références
Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9474-9
pubmed: 12093905
J Pharmacol Exp Ther. 2003 Aug;306(2):471-7
pubmed: 12724349
J Clin Invest. 2003 Jun;111(11):1783-91
pubmed: 12782680
J Clin Invest. 2006 Apr;116(4):1005-15
pubmed: 16585965
Circulation. 2007 Feb 13;115(6):763-72
pubmed: 17283256
Hypertension. 2007 May;49(5):962-70
pubmed: 17389260
Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):8277-81
pubmed: 1832775
N Engl J Med. 2008 Mar 27;358(13):1370-80
pubmed: 18367740
Mol Pharmacol. 2008 Sep;74(3):562-73
pubmed: 18523139
Circ Res. 2008 Oct 24;103(9):992-1000
pubmed: 18802028
Mol Pharmacol. 2009 Mar;75(3):713-28
pubmed: 19109357
J Biol Chem. 2009 Apr 24;284(17):11425-35
pubmed: 19153083
Pharmacol Ther. 2010 Oct;128(1):191-227
pubmed: 20438756
Experientia. 1990 Jan 15;46(1):81-4
pubmed: 2153573
Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19796-801
pubmed: 22089237
Cell Signal. 2012 Mar;24(3):794-802
pubmed: 22120526
J Biol Chem. 2012 Apr 13;287(16):12952-65
pubmed: 22371491
Mol Pharmacol. 2013 Apr;83(4):870-81
pubmed: 23364786
J Am Heart Assoc. 2014;3(2):e000145
pubmed: 24772522
PLoS One. 2015 Jan 21;10(1):e0115701
pubmed: 25606852
Am J Physiol Heart Circ Physiol. 2015 Sep;309(5):H888-96
pubmed: 26116709
PLoS One. 2017 Jan 12;12(1):e0168409
pubmed: 28081170
Circ Res. 2017 Mar 31;120(7):1103-1115
pubmed: 28219977
JACC Basic Transl Sci. 2017 Feb;2(1):39-53
pubmed: 28286875
Am J Physiol Heart Circ Physiol. 2017 Dec 1;313(6):H1109-H1118
pubmed: 28822963
J Biol Chem. 2018 Jun 8;293(23):8734-8749
pubmed: 29610273
Nat Rev Cardiol. 2018 Jul;15(7):387-407
pubmed: 29674714
Circ Res. 2018 Aug 31;123(6):716-735
pubmed: 30355236
Am J Physiol Heart Circ Physiol. 2019 Jan 1;316(1):H224-H232
pubmed: 30412439
J Mol Cell Cardiol. 2019 Feb;127:67-73
pubmed: 30528765
J Biol Chem. 1995 Apr 28;270(17):9828-32
pubmed: 7730363
Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8121-6
pubmed: 9223325
J Biol Chem. 1997 Dec 5;272(49):31051-7
pubmed: 9388255
Circulation. 1998 Apr 21;97(15):1488-95
pubmed: 9576430
Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10140-5
pubmed: 9707614